# Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

> **NCT00125034** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 344 (actual)

## Conditions studied

- Neoplasm Metastasis
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00125034
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-03
- **Final completion:** 2010-11
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125034, "Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00125034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*